Novel Insights into Pediatric Acute Lymphoblastic Leukemia Ophthalmic Relapses from a Nationwide Cohort Study

Le Louet, Solenne; Icart, Véronique; Strullu, Marion; Petit, Arnaud; Freycon, Claire; Blouin, Pascale; Serre, Jill; Rama, Nicolas; Reguerre, Yves; Piguet, Christophe; Pasquet, Marlène; David, Audrey; Simon, Pauline; Poiree, Marilyne; Carausu, Liana; Rialland, Fanny; Abouchahla, Wadih; Saultier, Paul; Ducassou, Stéphane; Valduga, Julie; Baruchel, André; Bertrand, Yves; Domenech, Carine

doi:10.7150/jca.64996



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2022; 13(4):1272-1281. doi:10.7150/jca.64996 This issue Cite

Research Paper

Novel Insights into Pediatric Acute Lymphoblastic Leukemia Ophthalmic Relapses from a Nationwide Cohort Study

Solenne Le Louet^1✉, Véronique Icart², Marion Strullu³, Arnaud Petit⁴, Claire Freycon⁵, Pascale Blouin⁶, Jill Serre⁶, Nicolas Rama⁷, Yves Reguerre⁸, Christophe Piguet⁹, Marlène Pasquet¹⁰, Audrey David¹¹, Pauline Simon¹², Marilyne Poiree¹³, Liana Carausu¹⁴, Fanny Rialland¹⁵, Wadih Abouchahla¹⁶, Paul Saultier¹⁷, Stéphane Ducassou¹⁸, Julie Valduga¹⁹, André Baruchel³, Yves Bertrand¹, Carine Domenech^1,7

1. Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, University-Lyon1, Lyon, France
2. Department of Pediatric Ophtalmology, Hopital Nord Ouest de Villefranche sur Saône, Gleize, France
3. Department of Pediatric Hematology, Hôpital Robert-Debré, Paris, France
4. Department of Pediatric Hematology, Hôpital Armand-Trousseau, Paris, France
5. Department of Pediatric Hematology, CHU Grenoble Alpes, Grenoble, France
6. Department of Pediatric Hematology, CHRU de Tours, Tours, France
7. Apoptosis, Cancer and Development Laboratory - Center of Research of Cancerology of Lyon, INSERM U1052-CNRS UMR5286, Lyon, France
8. Department of Pediatric Hematology, Centre hospitalier Félix-Guyon, Saint Denis de La Réunion, France
9. Department of Pediatric Hematology, CHU de Limoges, Limoges, France
10. Department of Pediatric Hematology, CHU de Toulouse, Toulouse, France
11. Department of Pediatric Hematology, CHU de Saint Etienne, Saint Etienne, France
12. Department of Pediatric Hematology, CHU de Besançon, Besançon, France
13. Department of Pediatric Hematology, CHU de Nice, Nice, France
14. Department of Pediatric Hematology, CHU de Brest, Brest, France
15. Department of Pediatric Hematology, CHU de Nantes, Nantes, France
16. Department of Pediatric Hematology, CHU de Lille, Lille, France
17. Department of Pediatric Hematology, Hôpital de la Timone, Marseille, France
18. Department of Pediatric Hematology, CHU de Bordeaux, Bordeaux, France
19. Department of Pediatric Hematology, CHRU de Nancy, Nancy, France

Citation:

Le Louet S, Icart V, Strullu M, Petit A, Freycon C, Blouin P, Serre J, Rama N, Reguerre Y, Piguet C, Pasquet M, David A, Simon P, Poiree M, Carausu L, Rialland F, Abouchahla W, Saultier P, Ducassou S, Valduga J, Baruchel A, Bertrand Y, Domenech C. Novel Insights into Pediatric Acute Lymphoblastic Leukemia Ophthalmic Relapses from a Nationwide Cohort Study. J Cancer 2022; 13(4):1272-1281. doi:10.7150/jca.64996. https://www.jcancer.org/v13p1272.htm

Other styles

Abstract

Ten to fifteen percent of children with acute lymphoblastic leukemia (ALL) relapse following treatment. Of these, less than 2% display ophthalmic relapses, which owing to their scarcity, are largely undocumented, leaving clinicians with few diagnostic and therapeutic recommendations, despite serious functional sequelae. We conducted a French multicenter retrospective study to collect all clinical, radiological, biological, and therapeutic data, and outcomes for children with ALL ophthalmic relapses. From 2000 to 2020, 20 ophthalmic relapses occurring after first-line therapy performed before January 1^st, 2017 were included in our study: 14 B-ALL and 6 T-ALL. Fifteen patients (75%) had concomitant involvement of the central nervous system, and 11 (55%) a combined bone marrow relapse. Only 1 had an isolated ophthalmic relapse. Eight children (40%) died, 7 from a refractory disease and 1 from toxic death, and 4 patients relapsed. With a median follow-up of 63.1 months, 8 patients are currently alive in continuous complete remission with only 2 displaying severe ophthalmic sequelae. Although rare, ophthalmic relapse could have a significant impact on the functional prognosis of survivors. Their management must be multidisciplinary, with a central role given to ophthalmologists.

Keywords: Childhood, ophthalmic relapse, ALL

Citation styles

APA

Le Louet, S., Icart, V., Strullu, M., Petit, A., Freycon, C., Blouin, P., Serre, J., Rama, N., Reguerre, Y., Piguet, C., Pasquet, M., David, A., Simon, P., Poiree, M., Carausu, L., Rialland, F., Abouchahla, W., Saultier, P., Ducassou, S., Valduga, J., Baruchel, A., Bertrand, Y., Domenech, C. (2022). Novel Insights into Pediatric Acute Lymphoblastic Leukemia Ophthalmic Relapses from a Nationwide Cohort Study. Journal of Cancer, 13(4), 1272-1281. https://doi.org/10.7150/jca.64996.

ACS

Le Louet, S.; Icart, V.; Strullu, M.; Petit, A.; Freycon, C.; Blouin, P.; Serre, J.; Rama, N.; Reguerre, Y.; Piguet, C.; Pasquet, M.; David, A.; Simon, P.; Poiree, M.; Carausu, L.; Rialland, F.; Abouchahla, W.; Saultier, P.; Ducassou, S.; Valduga, J.; Baruchel, A.; Bertrand, Y.; Domenech, C. Novel Insights into Pediatric Acute Lymphoblastic Leukemia Ophthalmic Relapses from a Nationwide Cohort Study. J. Cancer 2022, 13 (4), 1272-1281. DOI: 10.7150/jca.64996.

NLM

CSE

Le Louet S, Icart V, Strullu M, Petit A, Freycon C, Blouin P, Serre J, Rama N, Reguerre Y, Piguet C, Pasquet M, David A, Simon P, Poiree M, Carausu L, Rialland F, Abouchahla W, Saultier P, Ducassou S, Valduga J, Baruchel A, Bertrand Y, Domenech C. 2022. Novel Insights into Pediatric Acute Lymphoblastic Leukemia Ophthalmic Relapses from a Nationwide Cohort Study. J Cancer. 13(4):1272-1281.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.